DH — Definitive Healthcare Income Statement
0.000.00%
Last trade - 00:00
- $1.10bn
- $1.38bn
- $251.42m
- 53
- 31
- 51
- 41
2019 December 31st | 2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K/A | 10-K/A | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 85.5 | 118 | 166 | 223 | 251 |
Cost of Revenue | |||||
Gross Profit | 66.9 | 87.8 | 125 | 180 | 204 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 104 | 133 | 203 | 267 | 581 |
Operating Profit | -18 | -14.4 | -37.2 | -44 | -330 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -36.4 | -51.2 | -62.8 | -41.9 | -308 |
Provision for Income Taxes | |||||
Net Income After Taxes | -36.4 | -51.2 | -62.3 | -24.2 | -290 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -36.4 | -51.2 | -51.9 | -7.22 | -202 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -36.4 | -51.2 | -17.8 | -7.22 | -202 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.109 | -0.3 | -0.029 | 0.021 | -0.044 |
Dividends per Share |